Abstract
In man, the therapeutic effectiveness of specific inhibitors of leukotriene (LT) biosynthesis against allergen-induced bronchoconstriction appears to be related to thein vivo biochemical efficacy of these compounds, as measured by inhibition of whole blood LTB4 generation (upon A23187 stimulus) and, particularly, urinary LTE4 excretion. Accordingly, we have assessed the ability of two clinically documented LT biosynthesis inhibitors, zileuton and MK-886, and the structurally novel 5-lipoxygenase activatig protein antagonist, MK-0591, to inhibit the production of these inflammatory arachidonic acid metabolites in laboratory dogs. Zileuton (2 mg/kg) was extremely bioavailable in dogs (>10 μM plasma concentrations), and inhibited the A23187-inducedex vivo production of LTB4 by venous blood by >90%, in concordance with its potency in canine bloodin vitro (IC50=1.1 μM). Despite this degree of inhibition in whole blood, urinary LTE4 excretion was reduced by only 52%, a profile of activity similar to that seen in clinical studies. MK-886 was less well absorbed, with plasma concentrations of 3 μM being achieved only at 25 mg/kg. These levels resulted in <45% inhibition of LTB4 production, but a significant (p<0.05) 47% inhibition of urinary LTE4 excretion. MK-0591 was similarly bioavailable (compared with MK-886), but 10-fold more activein vivo as a 2 mg/kg dose resulted in 41–62% inhibition of urinary LTE4 excretion (p<0.05 vs controls;n=4, 28). Significant inhibition ofex vivo LTB4 synthesis was also observed at this dose (49%), in accord with peak plasma concentrations of 0.5 μM and anin vitro potency of 0.2–0.4 μM (IC50) in whole blood from these animals. At higher dose (10 mg/kg), MK-0591 inhibited LTE4 excretion by 69%, with 88% inhibition of the LT biosynthetic capacity of whole blood. These data demonstrate that the biochemical efficacy of structurally diverse leukotriene biosynthesis inhibitors can be assessedin vivo in normal laboratory dogs. Such measurements, combined with bioavailability data from other species, may be useful for predicting biochemical activity in man.
Similar content being viewed by others
References
J. R. Britton, S. P. Hanley and A. E. Tattersfiels,The effect of an oral leukotriene D 4 antagonist L-649,923 on the response to inhaled antigen in allergic asthma. J. Allergy Clin. Immunol.79:811–816 (1987).
J. S. Mann, C. Robinson, A. Q. Sheridan, P. Clement, M. K. Bach and S. T. Holgate,Effect of inhaled Piriprost (U-60,257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma. Thorx.41:746–752 (1986).
A. Sala, N. Voelkel, J. Maclouf, and R. C. Murphy,Leukotriene E 4 metabolism and elimination in normal human subjects. J. Biol. Chem.265, 21771–21778 (1990).
N. H. Maltby, G. W. Taylor, J. M. Ritter, K. Moore, R. W. Fuller and C. T. Dollery,Leukotriene C 4 elimination and metabolism in man. J. Allergy Clin. Immunol.85, 3–9 (1990).
M. Huber, J. Müller, I. Leier, G. Jedlitschky, H. A. Ball, K. P. Moore, G. W. Taylor, R. Williams and D. Keppler,Metabolism of cysteinyl leukotrienes in monkey and man. Eur. J. Biochem.194, 309–315 (1990).
P. Tagari, D. Ethier, M. Carry V. Korley, S. Charleson Y. Girard and R. Zamboni,Measurement of urinary leukotrienes by reversed-phase liquid chromatography and radio-immunoassay. Clin. Chem.35:388–391 (1989).
G. W. Taylor, P. Black, N. Turner, I. Taylor, N. H. Maltby, R. W. Fuller and C. T. Dollery,Urinary leukotriene E 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet1:584–588 (1989).
P. Tagari, J. B. Rasmussen, D. Delorme, Y. Girard, L.-O. Eriksson, S. Charleson and A. W. Ford-Hutchinson,Comparison of Urinary leukotriene E 4 and 16-carboxy-tetranordihydro LTE 4 excretion in allergic asthmatics after inhaled antigen. Eicosanoids3, 75–89 (1990).
J. Rokach, P. Tagari, D. Ethier, A. Foster, D. Delorme, J. L. Malo, A. Cartier, P. Manning, P. M. O'Byrne and Y. Girard,Identification and quantitation of leukotriene metabolites in animal and man. In: U. Zor, Z. Naor and A. Danon (Eds) New Trends Lipid Mediators Res. Karger, Basel3: 187–193 (1989).
P. J. Manning, J. Rokach, P.-L. Malo, D. Ethier, A. Cartier, Y. Girard, P. M. O'Byrne and S. Charleson,Urinary leukotriene E 4 levels during early and late asthmatic responses. J. Allergy Clin. Immunol.86, 211–220 (1990).
K. Sladek, R. Dworski, G. A. Fitzgerald, K. L. Buitkus, F. J. Blocks, S. R. Marney and R. J. Sheller,Allergen stimulated release of thromboxane A 2 and leukotriene E 4 in humans. Am. Rev. Respir. Dis.141, 1441–1445 (1990).
P. E. Christie, P. Tagari, A. W. Ford-Hutchinson, S. Charleson, P. Chee, J. P. Arm and T. H. Lee,Urinary leukotriene E 4 concentrations increase after aspirin challenge in aspirinsensitive subjects. Am. Rev. Respir. Dis.143, 1025–1029 (1991).
Y. Kikawa, S. Hosoi, I. Yasohiro, M. Sarto, A. Nakai, Y. Shigenaso, T. Hirao and M. Sudo,Exercise-induced urinary excretion of leukotriene E 4 in children with atopic asthma Pediatric Res. 29, 455–459 (1991).
V. Bellia, G. Cuttitta, A. Mirabella, M. Profita, A. Bonanno, G. Catania and G. Bonsignore,Urinary leukotriene E 4 as a marker for nocturnal asthma. Am. Rev. Respir. Dis145:A16 (1992).
J. Gaddy, R. K. Bush, D. Margolskee, V. C. Williams and W. Busse,The effects of a leukotriene D 4 antagonist in mild to moderate asthma. J. All. Clin. Immunol.85, 197A (1990).
P. J. Manning, R. M. Watson, D. J. Margolskee, V. C. Williams, J. I. Schwartz and P. M. O'Byrne,Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D 4-receptor antagonist. N. Engl. J. Med.323, 1736:1739 (1990).
J. B. Rasmussen, L. O. Eriksson, D. J. Margolskee, P. Tagari, V. C. Williams and K. E. Andersson,Leukotriene D 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J. Allergy Clin. Immunol.90:193–201 (1992).
B. Dahlen, M. Kumlin, H. Johansson, C. Larsson, O. Zetterstrom, K. Malmstrom, F. Brunner-Ferber, D. M. Margolskee and S.-E. Dahlen,The leukotriene antagonist MK-0679 improves baseline pulmonary function and block aspirin-induced airway obstruction in aspirin-sensitive asthmatics. Am. Rev. Respir. Dis.145:A15 (1992).
A. Shaw and R. D. Krell,Peptide leukotrienes: current status of research. J. Med. Chem.34, 1235–1242 (1991).
M. Carry, V. Korley, J. T. Willerson, L. Weigelt, A. W. Ford-Hutchinson and P. Tagari,Increased urinary leukotriene excretion in patients with cardiac ischemia: in vivo evidence for 5-lipoxygenase activation. Circulation85, 230–236 (1992).
S. Otsuji, H. Akagami and N. Shibata, (1988),The trend of leukotriene B 4 (LTB 4)in pulmonary arterial blood in acute myocardial infarction (AMI). Jpn. Circ. J.52, 840 (A4017 (1990).
J Y. Westcott, R. Thomas and N. F. Voelkel,Levels of urine leukotriene E 4 (LTE 4)are increased in püatients with ARDS. Am. Rev. Resp. Dis.141, A510 (1990).
J. Fauler, D. Tsikas, M. Holch, A. Seekamp, M. Nerlich, J. Sturm and J. C. Frolich,Enhanced synthesis of cysteinyl leukotrienes in polytraumatised patients with and without adult respiratory distress syndrome. Clin. Res.38, 484A (1990).
G. R. Bernard, V. Korley, P. Chee, B. Swindell, A. W. Ford-Hutchinson and P. Tagari,Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis144, 263–267 (1991).
K. Lauritsen,Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease. Danish. Med. Bull.36, 378–393 (1989).
K. V. Hackshaw, N. V. Voekl, R. B. Thomas and J. Y. Westcott,Urine leukotriene E 4 levels are elevated in patients with active systemic lupus erythematosus and scleroderma. Arthrit. Rheumatol. (in press).
H. R. Knapp,Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N. Engl. J. Med.323, 1745–1748 (1990).
K. P. Hui, I. K. Taylor, G. W. Taylor, P. Rubin, J. Kesterson, N. C. Barnes and P. J. Barnes,Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in allergic asthmatics thorax 46, 184–189 (1991).
B. S. Friedman, E. H. Bel, A. Buntinx, W. Tanaka, Y. R. Han, S. Shingo, R. Spector and P. J. Sterk,An oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am. Rev. Respir. Dis.141, 4 (1990).
R. H. Gundel, P. Kinkade, C. A. Torcellini, C. C. Clarke, J. Watrous, S. Desai, C. A. Homon, P. R. Farina and C. D. Wegner,Antigen-induced mediator relese in primates. Am. Rev. Respir. Dis.144, 76–82 (1991).
Y. Sakuma, H. Tsunoda, S. Katayama, S. Abe, I. Yamatsu and K. Katayam,Determination of plasma leukotrienes in antigen-induced bronchoconstrictive guinea-pigs. Prostaglandins41, 315–329 (1991).
P. Tagari, D. Ethier, A. Ford-Hutchinson and M. Cirino,Application of reversed phase high performance liquid chronmatography to the analysis of sulphidopeptide leukotrienes in pig bile. Biomed. Chromatog.4, 39–42 (1990).
A. Guhlmann, A. Keppler, S. Kastner, H. Krieter, U. B. Bruckner, K. Messmer and D. Keppler,Prevention of endogenous leukotriene production during anaphylaxis in the guinea pig by an inhibitor of leukotriene biosynthesis (MK-886) but not by dexamethasone. J. Exp. Med.170, 1905–1911 (1989).
A. Foster, G. Letts, S. Charleson, B. Fitzsimmons, B. Blacklock and J. Rokach,The in vivo production of peptide leukotrienes after pulmonary anaphylaxis in the reat. J. Immunol.141, 3544–3550 (1988).
J. R. Snapper, J. W. Coggeshal, W. E. Serafin, M. A. Phillips, P. L. Lefferts and B. W. Christman,Role of leukotrienes in an animal model of the adult respiratory distress syndrome. Advances in prostaglandin, Leukotriene and Thromboxane Res.17, 1043–1046 (1987).
B. D. Brewer, S. F. Clement, W. S. Lotz and R. Gronwall,Renal clearance, urinary excretion of endogenous substances, and urinary diagnostic indices in healthy noenatal foals. J. Vet. Int. Med.5:28–33 (1991).
P. Tagari, A. Becker, C. Brideau, R. Frenette, V. Sadl, E. Thomas, P. Vickers and A. Ford-Hutchinson,Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591. J. Pharmacol. Exp. Ther.265, 416–425 (1993).
D. K. Miller, J. W. Gillard, P. J. Vickers, S. Sadowski, C. Léveille, J. A. Mancini, P. Charleson, R. A. F. Dixon, A. W. Ford-Hutchinson, R. Fortin, J.-Y. Gauthier, J. Rodkey, R. Rozen, C. Rouzer, I. S. Sigal, C. D. Strader and J. F. Evans,Identification and isolation of a membrane protein necessary for leukotriene synthesis. Nature.343, 278–282 (1990).
R. A. F. Dixon, R. E. Diehl, E. Opas, E. Rands, P. J. Vickers, J. F. Evans, J. W. Gillard and D. K. Miller,Requirement of a 5-lipoxygenase activating protein for leukotriene synthesis. Nature343, 282–284 (1990).
G. W. Carter, P. R. Young, D. H. Albert, J. Bouska, R. Dyer, R. L. Bell, J. B. Summers and D. W. Brooks,5-lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther.256, 929–937 (1991).
C. Brideau, C. Chan, S. Charleson, D. Denis, J. F. Evans, A. W. Ford-Hutchinson, R. Fortin, J. W. Gillard, J. Guay, D. Guevremont, J. Hutchinson, T. Jones, S. Leger, J. Mancini, C. McFarlane, C. Pickett, H. Piechuta, P. Prasit, D. Riendeau, C. Rouzer, P. Tagari, P. Vickers, R. Young and W. Abraham.Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2, 2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can. J. Pharmacol.70, 799–807 (1992).
C. A. Rouzer, A. W. Ford-Hutchinson, H. Morton and J. W. Gillard,MK-886, a potent and specific leukotriene biosynthesis inhibitor, blocks and reverses the membrane association of 5-lipoxygenase in ionophore challenged leukocytes. J. Biol. Chem.265, 1436–1442 (1990).
J. Maclouf, C. Antoine, R. de Caterina, R. Sicari, R. C. Murphy, P. Patrignani, S. Loizzo and C. Patrono,Entry rate and metabolism of leukotriene C 4 into vascular compartment in healthy subjects. Am. J. Physiol.263, H244:249 (1992).
J. Y. Westcott, N. Voelkel and S. E. Wenzel,Inactivation of leukotriene C 4 in the airways and urinary leukotriene E 4 excretion in nanasthmatics and asthmatics. Am. Rev. Respir. Dis.145:A22 (1992).
J. Verhagen, E. H. Bel, G. M. Kijne, P. J. Sterk, P. L. B. Bruynzeel, G. A. Veldink and J. F. G. Vliegenthart,The excretion of leukotriene E 4 into urine following inhalation of leukotriene D 4 by human individuals. Biochem. Biophys. res. Comm.148:864–868 (1988).
T. Izumi, Z. Honda, N. Ohishi, S. Kitamura, S. Tsuchida, K. Sato, T. Shimiozu and Y. Seyama,Sulubilisation and partial purification of leukotriene C 4 synthase from guinea-pig lung: a microsomal enzyme with high specificity towards 5,6-epoxide leukotriene A 4. Biochimica Biophysica Acta959:305–315 (1988).
J. M. Balcarek, T. W. Theisen, M. N. Cook, A. Varrichio, S. M. Hwang, M. Strohsacker and S. T. Crooke,Isolation and characterisation of a cDNA clone encoding rat 5-lipoxygenase. J. Biol. Chem.263: 13937–13941 (1988).
M. Kumlin and S.-E. Dahlen,Differences in the formation and metabolism of leukotrienes B 4 and C 4 in the human lung. Biochem. Biophys. Acta.1044, 201–210 (1990).
W. Hagman and D. Keppler,Leukotrienes and other eicosanoids in liver pathophysiology. In: I.M. Arias, Jakoby, H. Popper, D. Schachter and D. A. Shatntz. The Liver: Biology and Pathobiology, pp 793–806 (1988).
K. P. Moore, J. Wood, C. Gove, K. C. Tan, J. Eason, G. W. Taylor and R. Williams,Synthesis and metabolism of cysteinyl leukotrienes by the isolated pig kidney. Kidney International.41, 1543–1548 (1992).
E. Kimble, T. Kowalski, D. White, A. Raychauduri, G. Pastor, H. Chertok, W. Lee, R. Neale, A. Hamdan and J. Wasley,CGS 22745: a selective orally active inhibitor of 5-lipoxygenase. Agents Actions34, 125–128 (1991).
W. Tanaka, A. Dallob, G. Winchell, W. Kline, R. Spector, T. Bjornsson and P. DeSchepper,Safety, pharmacokinetics and leukotriene B 4 (LTB 4)inhibition after MK-886 administration in normal male volunteers. Am. Rev. Respir. Dis.141, A32 (1990).
E. de Jong, I. van Vlijmen, J. Scholte, A. Buntinx, B. Friedman, W. Tanaka and P. van de Kerkhof,Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK-886) in psoriasis. Skin. Pharmacol.4:278–285 (1991).
P. R. Young, R. L. Bell, C. Lanni, J. B. Summers, D. W. Brooks and G. W. Carter,Inhibition of leukotriene biosynthesis in the rat peritoneal cavity. Eur. J. Pharmacol.205, 259–266 (1991).
Z. Diamant, M. C. Timmers, H. van der Veen, B. S. Friedman, M. De Smet, W. Tanaka, M. Depre, E. H. Bel, J. H. Dijkman and P. J. Sterk,The effect of MK-0591, a potent oral leukotriene biosynthesis inhibitor on allergen-induced airway responses in asthmatic subjects. Am. Rev. Respir. Dis.147, A446 (1983).
W. Tanaka, A. Dallob, B. S. Friedman, E. B. Brecher and J. R. Seibold,Biochemical activity of a potent, orally active leukotriene biosynthesis inhibitor (MK-0591) in health male volunteers. Proceedings ProstaglandinsVIII A643 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tagari, P., Brideau, C., Chan, C. et al. Assessment of thein vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. Agents and Actions 40, 62–71 (1993). https://doi.org/10.1007/BF01976753
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01976753